Director Trades
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Probiotec.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Results show revenue is growing in first half, but profitability still elusive
Health & Biotech
ASX Health Stocks: Dimerix commences Phase 3 trial, while IDT scoots 10pc after restoring profit
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
ScoPo’s Powerplays: Biogen drama, M&A action, and profit-taking coloured the week in healthcare
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Experts
Microcap magic: From iron ore to edtech (and IPOs) with Annapurna’s Stephen Scott
News
10 at 10: These ASX stocks are the focal point this morning – thanks to the Pfizer vaccine news
Health & Biotech
The pandemic could be a watershed moment for wellness products
Health & Biotech
Health: Wheeler dealer Probiotec spending money to make money
Health & Biotech
When your guts have gone nuts, who do you call? These ASX stocks are fighting gastrointestinal disease
Health & Biotech
Health: GTG back in with breast cancer, hopes to start sales next year
News
Trading Places: More investors follow WiseTech founder into Kyckr
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Probiotec shares just hit their highest point in nearly a decade
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Probiotec made a $12.9m half-year profit but 91pc of it was from businesses it has sold
Health & Biotech
